Neoadjuvant Darovasertib in Primary Uveal Melanoma
Study sponsor: IDEAYA Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2030-10Estimated
Enrollment · participants520Estimated
Source updated2026-05-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.